What Is Leqvio (Inclisiran)?

Leqvio, known generically as inclisiran, is one of the more interesting cholesterol medications to come along in years, mostly because of how little you have to think about it: after the first couple of doses, it's an injection you get just twice a year. It represents a genuinely new approach to lowering LDL, and it's worth understanding what it does, who it's for, and where it fits alongside everything else, including food.

What is Leqvio and how does it work?

Leqvio is a twice-yearly injection that lowers LDL cholesterol by switching off production of a protein called PCSK9. To see why that matters, you have to know what PCSK9 does. Your liver clears LDL from your blood using LDL receptors, little docking stations that grab LDL particles and pull them out of circulation. PCSK9 is a protein that destroys those receptors. So the more PCSK9 you have, the fewer receptors survive, and the higher your LDL climbs.

Leqvio is a type of therapy called small interfering RNA, or siRNA. It works inside your liver cells to block the instructions for making PCSK9 before the protein is ever built. With less PCSK9 around, more LDL receptors survive to do their job, and your LDL falls. It's a clever bit of biology: rather than removing a harmful protein, it quietly stops that protein from being made in the first place.

How well does Leqvio lower cholesterol?

Substantially. In the large clinical trials, Leqvio lowered LDL by roughly 50 percent in people already taking a statin, and real-world use has shown reductions in the 40 to 45 percent range. Either way, that's a big drop, on par with the other most powerful non-statin drugs, and it holds steady between doses.

What makes Leqvio different from other cholesterol drugs?

The dosing schedule, above all. Most cholesterol medications are a daily pill or, in the case of the other PCSK9 drugs, an injection every two to four weeks. Leqvio is given as an injection at the start, again at three months, and then only twice a year after that. For many people that means two appointments a year and nothing to remember in between, which sidesteps the single biggest problem in cholesterol treatment: people stopping their medication or forgetting doses.

It helps to see where Leqvio sits among the newer options. It's one of a family of drugs that target PCSK9, and I've written about the whole group in cholesterol medications beyond statins. The injectable antibodies Repatha and Praluent work by mopping up PCSK9 protein that's already been made, and there's now an oral PCSK9 pill, Lipfendra, as well. Leqvio's angle is different: it shuts off PCSK9 production at the source, which is what buys the long gap between doses.

Who is Leqvio for?

People who need more LDL lowering than a statin alone can give them. It was first approved for adults with established cardiovascular disease or an inherited high-cholesterol condition called heterozygous familial hypercholesterolemia, in both cases as an add-on when a maximally tolerated statin isn't getting LDL to goal. More recently its use was expanded to include people with elevated LDL and increased heart-disease risk who haven't yet had an event, again as an adjunct to diet and a statin. It is not a first-line treatment and it's not a statin replacement; it's a powerful addition when diet and statins leave you short of your target.

What are the side effects?

Generally mild. The most common is a reaction at the injection site, redness, mild pain, or a rash, along with occasional joint aches. Because it's given by a healthcare provider rather than taken at home, there's no daily routine to manage and little room for dosing error. As with any newer medication, the long-term safety record is still being written, but the profile so far is reassuring.

Where does food fit in?

Right at the foundation, as always. A drug like Leqvio is a genuine advance for people who need aggressive LDL lowering, and if you and your doctor decide you need it, that's a good and reasonable decision. But it's worth remembering what every one of these drugs, including Leqvio, is ultimately trying to do: get more LDL receptors working so your body clears more cholesterol. Food nudges that same system. The unsaturated fats in nuts and seeds support LDL-receptor activity, while fiber and plant sterols pull cholesterol out through a separate pathway entirely.

The practical point is that the two approaches work together. Eating well doesn't compete with a medication like Leqvio; it lowers the starting point, which often means reaching your goal with less medication overall, and it improves your blood pressure, blood sugar, weight, and inflammation at the same time, which no cholesterol drug does. That's the whole idea behind Step One Foods: whatever else your treatment plan includes, food is working on the same machinery, in the same direction, every day.

If you're new to this site and found this useful, I write one of these evidence-based articles every week. You can get them in your inbox by joining my email list at the bottom of this page. No spam, no requirement to buy anything, just practical knowledge.